P. Aimone

发表

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

C. Gridelli, S. Thongprasert, E. Felip, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

E. di Tomaso, P. Aimone, C. Massacesi, 2016, OncoTargets and therapy.

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

S. Voloshin, M. Mauro, N. Chaudhri, 2021 .

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

J. Radich, F. Giles, G. Saglio, 2021, Leukemia.

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx).

N. Raj, N. Fazio, P. Ruszniewski, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.

G. Scambia, P. Scollo, P. Aimone, 2010, European journal of cancer.

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

E. Felip, D. Planchard, L. Paz-Ares, 2016 .

Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET).

S. Libutti, R. Salazar, E. Baudin, 2015 .

A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.

K. Yoo, H. Shimada, C. Zwaan, 2021, Blood advances.

Phase 2 Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.

K. Yoo, H. Shimada, C. Zwaan, 2019, Blood.

Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma

R. Motzer, P. Russo, C. Sternberg, 2018, Clinical Cancer Research.

A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.

S. Libutti, E. Baudin, L. Antonuzzo, 2016, Anticancer research.

Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment

M. Quinlan, Masahiko Sato, P. Aimone, 2021, Journal of clinical pharmacology.

Pharmacokinetics of Asciminib When Taken With Imatinib or With Food

M. Quinlan, S. Dodd, P. Aimone, 2021, Clinical pharmacology in drug development.

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

Sung-Bae Kim, A. Dechaphunkul, É. Remenár, 2017, The Lancet. Oncology.

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

E. di Tomaso, P. Aimone, C. Massacesi, 2016, OncoTargets and therapy.

A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs.

J. Cortes, M. Mauro, A. Hochhaus, 2021, Blood.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

R. Motzer, P. Russo, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).

R. Motzer, P. Russo, R. Motzer, 2017 .

A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).

M. Voss, J. Infante, S. Chowdhury, 2017 .

A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma.

M. Voss, S. Chowdhury, R. Hawkins, 2021, Clinical genitourinary cancer.

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study

Robin L. Jones, A. Cesne, S. George, 2020, British Journal of Cancer.

Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study

J. Lipton, O. Ottmann, M. Breccia, 2020, Leukemia & lymphoma.

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

I. Flinn, R. Larson, R. Clark, 2021, Leukemia.

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

J. Cortes, M. Deininger, D. DeAngelo, 2018, Blood.

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

M. Heinrich, J. Cortes, M. Deininger, 2020 .

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom

J. Radich, F. Giles, G. Saglio, 2020 .

Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study.

J. Radich, S. Acharyya, F. Giles, 2019, Journal of Clinical Oncology.

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.

R. Motzer, P. Russo, T. Choueiri, 2021, European urology.

Estimand framework: Are we asking the right questions? A case study in the solid tumor setting

A. Ravaud, R. Motzer, M. Casey, 2020, Pharmaceutical statistics.

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

I. Flinn, R. Larson, R. Clark, 2019, Blood.

BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Sung-Bae Kim, A. Dechaphunkul, É. Remenár, 2016 .

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

R. Motzer, P. Russo, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

T. Halfdanarson, P. Aimone, C. Yoo, 2024, Journal of Clinical Oncology.